SGRQ total | EQ 5D VAS | UCSD-SOBQ | WHO-5 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
beta | 95% CI | p-value | beta | 95% CI | p-value | beta | 95% CI | p-value | beta | 95% CI | p-value | |
Female sex | 5.42 | 1.13; 9.71 | 0.013 | −3.36 | −6.90; 0.18 | 0.063 | 13.56 | 6.41; 20.72 | < 0.001 | − 1.47 | −2.60; − 0.33 | 0.011 |
Age | 0.00 | −0.19; 0.20 | 0.963 | −0.18 | − 0.34; − 0.02 | 0.029 | 0.35 | 0.04; 0.66 | 0.026 | −0.05 | − 0.10; 0.00 | 0.074 |
Age at first symptom onset in years | −0.10 | − 0.28; 0.08 | 0.285 | − 0.08 | − 0.22; 0.07 | 0.323 | 0.17 | − 0.11; 0.46 | 0.238 | − 0.03 | − 0.07; 0.02 | 0.299 |
Age at diagnosis in years | −0.09 | − 0.28; 0.09 | 0.320 | − 0.08 | − 0.23; 0.07 | 0.290 | 0.18 | − 0.11; 0.48 | 0.227 | − 0.02 | − 0.07; 0.03 | 0.400 |
Duration since first symptoms in years | 0.73 | 0.28; 1.18 | 0.002 | −0.51 | −0.89; − 0.13 | 0.008 | 0.71 | − 0.04; 1.46 | 0.062 | − 0.09 | − 0.21; 0.03 | 0.139 |
Disease duration in months | 1.36 | 0.70; 2.02 | < 0.001 | −1.10 | − 1.65; −0.55 | < 0.001 | 1.70 | 0.64; 2.77 | 0.002 | −0.25 | −0.43; − 0.08 | 0.005 |
< 3 months | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
3 to < 6 months | −2.63 | −9.30; 4.04 | 0.440 | 1.30 | −4.28; 6.89 | 0.647 | −4.48 | −16.06; 7.11 | 0.449 | 0.54 | −1.27; 2.34 | 0.560 |
More than 6 months | 6.54 | 2.53; 10.55 | 0.001 | −5.10 | −8.43; − 1.76 | 0.003 | 8.43 | 1.74; 15.12 | 0.014 | −0.68 | −1.76; 0.40 | 0.215 |
Number of comorbidities | ||||||||||||
None | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
1 | 3.55 | −1.37; 8.47 | 0.157 | −5.19 | −9.23; − 1.16 | 0.012 | 9.93 | 2.05; 17.80 | 0.013 | −0.86 | −2.16; 0.44 | 0.195 |
2 | 4.49 | −0.63; 9.61 | 0.086 | −6.46 | −10.66; −2.26 | 0.003 | 10.11 | 1.88; 18.34 | 0.016 | −1.02 | −2.37; 0.33 | 0.140 |
3 | 5.87 | −0.04; 11.78 | 0.051 | −7.75 | − 12.62; −2.88 | 0.002 | 15.37 | 5.74; 24.99 | 0.002 | −1.98 | −3.55; −0.41 | 0.013 |
4+ | 17.18 | 10.14; 24.23 | < 0.001 | −14.99 | −20.88; −9.11 | < 0.001 | 33.06 | 20.77; 45.35 | < 0.001 | −4.35 | −6.24; −2.46 | < 0.001 |
NHYA | ||||||||||||
I | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
II | 16.07 | 9.16; 22.98 | < 0.001 | −12.61 | −19.06; −6.15 | < 0.001 | 22.28 | 10.78; 33.77 | < 0.001 | −1.86 | −3.92; 0.21 | 0.078 |
III | 26.95 | 19.97; 33.93 | < 0.001 | −18.00 | −24.49; − 11.50 | < 0.001 | 38.29 | 26.65; 49.92 | < 0.001 | −3.82 | −5.90; − 1.75 | < 0.001 |
IV | 33.28 | 16.44; 50.13 | < 0.001 | −27.35 | −41.90; − 12.81 | < 0.001 | 51.63 | 24.63; 78.64 | < 0.001 | −8.69 | −13.43; − 3.95 | < 0.001 |
6MWD (m) | − 0.01 | − 0.01; 0.00 | 0.217 | 0.00 | 0.00; 0.01 | 0.313 | −0.01 | − 0.03; 0.00 | 0.109 | 0.00 | 0.00; 0.00 | 0.423 |
FEV1% predicted | −0.55 | −0.62; − 0.49 | < 0.001 | 0.43 | 0.37; 0.49 | < 0.001 | − 0.80 | − 0.91; − 0.70 | < 0.001 | 0.09 | 0.07; 0.11 | < 0.001 |
FVC % predicted | − 0.60 | − 0.66; − 0.53 | < 0.001 | 0.46 | 0.39; 0.53 | < 0.001 | −0.89 | −1.00; − 0.78 | < 0.001 | 0.11 | 0.09; 0.13 | < 0.001 |
DLCO % predicted | −0.26 | − 0.31; − 0.20 | < 0.001 | 0.26 | 0.20; 0.33 | < 0.001 | − 0.35 | − 0.44; − 0.25 | < 0.001 | 0.04 | 0.02; 0.06 | < 0.001 |
Change in FVC % predicted between baseline and 1-year follow-up | ||||||||||||
Stable/increase | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
Decrease by 0 to 10% | 3.71 | −0.55; 7.97 | 0.087 | −2.90 | −6.58; 0.77 | 0.122 | 4.08 | −3.13; 11.29 | 0.267 | −0.51 | −1.67; 0.65 | 0.393 |
Decrease by > 10% | 9.08 | 2.48; 15.67 | 0.007 | −8.07 | −13.81; −2.33 | 0.006 | 11.24 | 0.32; 22.16 | 0.044 | −1.30 | −3.09; 0.50 | 0.156 |
Change in DLCO % predicted between baseline and 1-year follow-up | ||||||||||||
Stable/increase | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
Decrease by 0 to 10% | 5.46 | 0.85; 10.08 | 0.020 | −0.41 | −4.43; 3.60 | 0.841 | 10.46 | 2.85; 18.07 | 0.007 | −0.37 | −1.62; 0.88 | 0.561 |
Decrease by > 10% | 7.79 | 0.85; 14.73 | 0.028 | −3.93 | −9.96; 2.10 | 0.201 | 10.74 | −0.73; 22.21 | 0.067 | −0.40 | −2.28; 1.47 | 0.673 |
Change in FVC % predicted between baseline and last follow-up | ||||||||||||
Stable/increase | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
Decrease by 0 to 10% | 3.44 | −1.04; 7.92 | 0.133 | −3.30 | −7.08; 0.48 | 0.087 | 3.18 | −4.45; 10.81 | 0.414 | −0.22 | −1.44; 0.99 | 0.719 |
Decrease by > 10% | 7.47 | 2.11; 12.83 | 0.006 | −6.50 | −11.02; − 1.99 | 0.005 | 8.80 | −0.15; 17.75 | 0.054 | −0.87 | −2.32; 0.59 | 0.242 |
Change in DLCO % predicted between baseline and last follow-up | ||||||||||||
Stable/increase | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
Decrease by 0 to 10% | 4.41 | −0.52; 9.35 | 0.080 | −1.42 | −5.59; 2.75 | 0.505 | 11.09 | 2.94; 19.23 | 0.008 | −0.44 | −1.77; 0.89 | 0.518 |
Decrease by > 10% | 5.10 | −0.51; 10.72 | 0.075 | −2.47 | −7.18; 2.25 | 0.305 | 8.24 | −0.88; 17.36 | 0.077 | −0.30 | −1.80; 1.21 | 0.701 |
GAP index | 3.29 | 1.95; 4.64 | < 0.001 | −3.41 | −4.50; −2.33 | < 0.001 | 6.47 | 4.36; 8.58 | < 0.001 | −0.50 | − 0.86; − 0.14 | 0.007 |
Stage I | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
Stage II | 5.69 | 0.74; 10.63 | 0.024 | −7.04 | −11.00; −3.08 | < 0.001 | 16.51 | 8.69; 24.34 | < 0.001 | −0.92 | −2.25; 0.41 | 0.177 |
Stage III | 12.93 | 7.42; 18.45 | < 0.001 | −13.51 | − 17.96; −9.07 | < 0.001 | 25.78 | 17.08; 34.47 | < 0.001 | − 1.79 | −3.27; −0.30 | 0.019 |
Overall physician’s judgement of clinical course of IPF | ||||||||||||
Stable disease | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
Slow progression | 7.79 | 3.51; 12.06 | < 0.001 | −3.52 | −7.14; 0.10 | 0.056 | 11.13 | 4.04; 18.21 | 0.002 | −1.08 | −2.23; 0.08 | 0.068 |
Rapid progression | 13.16 | 6.22; 20.11 | < 0.001 | −9.52 | −15.39; −3.65 | 0.001 | 19.89 | 8.32; 31.47 | 0.001 | −2.72 | −4.61; −0.83 | 0.005 |
No judgement possible | −0.39 | −4.93; 4.15 | 0.865 | 1.33 | −2.43; 5.09 | 0.487 | 1.72 | −5.72; 9.15 | 0.651 | −0.01 | −1.23; 1.20 | 0.986 |